Navigation Links
Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
Date:5/10/2011

ROCKVILLE, Md., May 10, 2011 /PRNewswire/ --Neuralstem, Inc. (NYSEAmex: CUR)  reported its financial results for the three months period ended March 31, 2011 and provided a business and clinical update.  

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"The Company reached several major milestones in the first Quarter of 2011.  Interim data from our Phase I trial for ALS was presented at the American Academy of Neurology Annual Meeting in April, where the principal investigator of the trial, Dr. Eva Feldman, reported the ground-breaking work was both feasible and safe," said Neuralstem's Chairman and Chief Scientific Officer Karl Johe, PhD. "We completed all of the transplantations for the first 12-patient cohort in our ALS trial in mid-April. Also, in February, the U.S. FDA Office of Orphan Products Development granted the Company orphan drug designation for the cell therapy treatment of ALS with its human spinal cord-derived neural stem cells (NSI-566RSC)."

"Further, after receiving approval from the FDA late in 2010 for our first small molecule drug  trial, NSI-189 for major depression, we began dosing in our phase 1a patients in February," said Dr. Johe. "Looking forward, we expect the FDA to approve the second part of the Phase I ALS trial this summer. The next group of patients will receive injections in the upper spinal cord area, where we believe that the injections can ultimately aid in the preservation of respiratory capacity for ALS patients. Additionally, we expect the NSI-189 major depression trial to proceed to Phase Ib with escalating dosing of depressed patients this summer.  The small molecule program has been strengthened by the addition of Maurizio Fava, MD, Director of the Massachusetts General Hospital Department of Psychiatry Clinical Trials Network and Institute, who is now consulting on the trial des
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
2. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
3. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
4. Neuralstem Completes $5.25 Million Financing
5. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
6. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
8. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
9. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
10. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
11. Neuralstem Reports Second Quarter Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 2014 The report “Service Quality Management ... & Provider Type - Global Advancements, Worldwide Forecasts & ... in-depth analysis and forecasting of revenues. , Browse ... pages and in-depth TOC on “Service Quality Management (SQM) ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. ... marketer of proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the "Company"), ... of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
(Date:12/24/2014)... 23, 2014 SoundConnect’s ... introduce cutting edge communication technology, provide continued education ... This webinar series demonstrates online communication features and ... web conferencing’s most innovative and powerful tools. , ...
(Date:12/24/2014)... December 23, 2014 Nashville Fertility Center announced ... for the American Society for Reproductive Medicine (ASRM), a leading ... medicine. In his new role as treasurer, Dr. Hill ... have a voice in furthering the mission of ASRM. ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... Neogen Corporation (Nasdaq: NEOG ) announces ... Results WebcastWhen: Thursday, March 19, 2009 @ ... Live over the Internet -- Simply log on ... Contact: Terry Maynard of Neogen Corporation, +1-800-234-5333.If ...
... expands to EU, LATAM and AfricaSAINT JOHN, New Brunswick, ... immediate availability of ThyroChek, the rapid test for elevated ... in the European Union. Until now, it has only ... test for adults to the 200,000 physician office labs. ...
... Inc. (Nasdaq: INSM ), a developer of follow-on biologics (FOB) and ... Company Highlights , , ... Insmed entered into a definitive agreement with ... related to Insmed,s follow-on biologics platform. , ...
Cached Biology Technology:SD Canada Announces CE Mark for ThyroChek(R) Adult and NeoNatal Tests 2Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 10
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced ... 2015-2019" report to their offering. ... a technology used for the identification of individuals. Facial ... person such as nose, jaw edges, mouth, and the ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... of the marine food chain, albatrosses accumulate toxic contaminants ... A new study has found dramatic differences in contaminant ... in different areas of the North Pacific. Researchers also ... in both species over the past ten years. , ...
... scrubbing off and discarding the outer layer of long-grain ... the first time, scientists in Japan have shown that ... significantly lowers blood pressure in rats whose hypertension resembles ... in the March 8 issue of the Journal ...
... a blueprint for boosting anti-cancer drugs' effectiveness and lowering ... sinker onto the drugs. This extra weight makes the ... Chemotherapy drugs often fall short of achieving their full ... the tumor too rapidly, said the scientists from Duke ...
Cached Biology News:Albatross study shows regional differences in ocean contamination 2Albatross study shows regional differences in ocean contamination 3How nice, brown rice: Study shows rice bran lowers blood pressure in rats 2Weighting cancer drugs to make them hit tumors harder 2Weighting cancer drugs to make them hit tumors harder 3Weighting cancer drugs to make them hit tumors harder 4
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... Analysis of large numbers of samples may ... system which requires minimum operator attention. ... PowerStream software and interface CE 4900. The ... operates in Windows XP and Windows 98 and ...
Biology Products: